Mitchell Ho, Ph.D

Mitchell Ho, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


Dr. Ho has pioneered the generation of therapeutic antibodies that target cancer-associated heparan sulfate proteoglycans. A focus of his work is on the characterization of cell surface glypicans such as GPC3, GPC2 and GPC1 as new therapeutic targets in cancer. This area of research ranges from investigation of the mechanisms by which glypicans regulate Wnt, Yap and other signaling molecules to the design of antibody-based cancer therapies. He established mammalian cell surface display and built shark and camel single domain antibody phage libraries as new tools to advance antibody engineering and drug discovery. The antibodies and CAR T cells created in his lab are being tested at clinical stages for treating liver cancer, neuroblastoma, mesothelioma and other cancers. Dr. Ho is also Director of the NCI CCR Antibody Engineering Program.

Areas of Expertise

1) glypicans and heparan sulfate proteoglycans 2) mesothelin 3) Wnt, Yap and signal transduction 4) antibody and protein engineering 5) single domain antibodies and nanobodies 6) CAR T cells and cell-based immunotherapy 7) mammalian cell surface display 8) immunotoxin


Selected Recent Publications

CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.

Li N, Torres MB, Spetz MR, Wang R, Peng L, Tian M, Dower CM, Nguyen R, Sun M, Tai CH, de Val N, Cachau R, Wu X, Hewitt SM, Kaplan RN, Khan J, St Croix B, Thiele CJ, Ho M.
Cell Rep Med. 2: 100297, 2021.
Full-Text Article
[ Journal Article ]

Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice

Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropublic B, Hewitt SM, Orentas RJ, Greten TF, Ho M.
Gastroenterology. doi: 10.1053/j: 2020. [ Journal Article ]

Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M.
Proc Natl Acad Sci U S A.. doi: 10.1073/pnas.1706055114., 2017. [ Journal Article ]

Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis

Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M
Nat. Commun.. 6: 6536, 2015. [ Journal Article ]

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma

Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.
Proc Natl Acad Sci U S A.. 110 (12): E1083-91, 2013. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.